Science
Estela Rodriguez: FDA Approval Is Only the First Step Toward Patient Access
Estela Rodriguez/X

Estela Rodriguez: FDA Approval Is Only the First Step Toward Patient Access

Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared on X:

“Approval is only the first step. Access is the finish line. Excellent jco piece by I.DagogoJackMD and an important call to action to ensure post-approval operational readiness after novel drug approvals.

We can’t celebrate FDA approval if patients still can’t access the therapy.

Sunvozertinib and daraxonrasib are timely examples of the gap between regulatory approval and real-world availability.”

Title: Speeding to a Stop: Postapproval Barriers to Accessing New Lung Cancer Therapies

Author: Ibiayi Dagogo-Jack

Read the full article.

You can also read:

Daraxonrasib Opens a Broader RAS-Targeting Strategy in Previously Treated NSCLC

Estela Rodriguez: FDA Approval Is Only the First Step Toward Patient Access

cancer DaraxONRASib Estela Rodriguez FDA FDA approval I.DagogoJackMD Ibiayi Dagogo-Jack JCO Lung cancer OncoDaily Oncology Sunvozertinib